1. Falagas ME, Grammatikos AP, Michalopoulos A: Potential of oldgeneration
antibiotics to address current need for new antibiotics.
Expert Rev Anti Infect Ther 2008; 6(5): 593-600
2. Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related
peptide antibiotics. Ann Rev Biochem 1977;46:723-763
3. Landman D1, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M,
Quale J: Evolution of antimicrobial resistance among Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in
Brooklyn, NY. J Antimicrob Chemother 2007; 60:78-82
4. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F,
Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S,
Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson
DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma
M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner
M, Welfare W, Livermore DM, Woodford N: Emergence of a new
antibiotic resistance mechanism in India, Pakistan, and the UK: A
molecular, biological, and epidemiological study. Lancet Infect Dis
2010; 10(9): 597-602
5. Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC: Polymyxinresistant
Acinetobacter spp. isolates: What is next? Emerg Infect
Dis 2003; 9(8): 1025-1027
6. Karbuz A, Ozdemir H, Yaman A, Kocabaş BA, Odek C, Güriz H,
Aysev AD, Ciftçi E, Kendirli T, Ateş C, Ince E: The use of colistin in
critically ill children in a pediatric intensive care unit. Pediatr Infect
Dis J 2014; 33(1): e19-24
7. Benifla M, Zucker G, Cohen A, Alkan M: Successful treatment
of Acinetobacter meningitis with intrathecal polymyxin E. J
Antimicrob Chemother 2004; 54(1): 290-292
8. Yagmur R, Esen F: Intrathecal colistin for treatment of Pseudomonas
aeruginosa ventriculitis: Report of a case with successful outcome.
Crit Care 2006; 10(6): 428
9. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A,
Elmdaghri N, Belabbes H, Benbachir M: Colistin and rifampicin
in the treatment of nosocomial infections from multiresistant
Acinetobacter baumannii. J Infect 2006; 53(4): 274-278
10. Karakitsos D, Paramythiotou E, Samonis G, Karabinis A: Is
intraventricular colistin an effective and safe treatment for postsurgical
ventriculitis in the intensive care unit? Acta Anaesthesiol
Scand 2006; 50(10): 1309-1310
11. Fass RJ, Barnishan J, Ayers LW: Emergence of bacterial resistance
to imipenem and ciprofloxacin in a university hospital. J Antimicrob
Chemother 1995; 36(2): 343-353
12. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues
E, Sauaia N, Boulos M: An outbreak of multiresistant Acinetobacter
baumanii in a university hospital in São Paulo, Brazil. Infect Control
Hosp Epidemiol 1996; 17(6): 366-368
13. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ,
Bragagnolo KL, Rea-Neto A, Penteado-Filho SR, Livermore DM,
Woodford N: Outbreak of carbapenem-resistant Acinetobacter
baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J
Clin Microbiol 2003; 41(7): 3403-3406
14. Kulah C, Mooij MJ, Comert F, Aktas E, Celebi G, Ozlu N,
Rijnsburger MC, Savelkoul PH: Characterisation of carbapenemresistant
Acinetobacter baumannii outbreak strains producing
OXA-58 in Turkey. Int J Antimicrob Agents 2010; 36(2): 114-118
15. Colestimetato de Sódio (Coly-Mycin M)/ FDA: Information for
Healthcare Professionals Colistimethate (Coly-Mycin M and
generic products). Rockville: Food and Drug Administration; 2007.
[cited 2007 jun 28]. Available from: URL:http://www.fda.gov/cder/
drug/InfoSheets/HCP/colistimethateHCP.htm
16. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa
MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation
RL, Li J, Zavascki AP: Population pharmacokinetics of intravenous
polymyxin B in critically ill patients: Implications for selection of
dosage regimens. Clin Infect Dis 2013; 57(4):524-531
17. Hoeprich PD: The polymyxins. Med Clin North Am 1970; 54(5):
1257-1265
18. Li J, Rayner CR, Nation RL: Colistin-associated acute renal failure:
Revisited. South Med J 2005; 98(12): 1229-1230
19. Sarria JC, Angulo-Pernett F, Kimbrough RC, McVay CS, Vidal AM:
Use of intravenous polymyxin B during continuous venovenous
hemodialysis. Eur J Clin Microbiol Infect Dis 2004; 23(4): 340-341
20. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P,
Michalopoulos A: Effectiveness and nephrotoxicity of colistin
monotherapy vs. colistin-meropenem combination therapy for
multidrug-resistant Gram-negative bacterial infections. Clin
Microbiol Infect 2006; 12(12): 1227-1230
21. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, Grau S,
Riu M, Sala M, Knobel H: Effectiveness and safety of colistin
for the treatment of multidrug-resistant Pseudomonas aeruginosa
infections. Infection 2009; 37(5): 461-465
22. Ouderkirk JP, Nord JA, Turett GS, Kislak JW: Polymyxin B
nephrotoxicity and efficacy against nosocomial infections caused
by multiresistant gram-negative bacteria. Antimicrob Agents
Chemother 2003; 47(8): 2659-2662
23. Yahav D, Farbman L, Leibovici L, Paul M: Colistin: New lessons
on an old antibiotic. Clin Microbiol Infect 2012; 18(1): 18-29
25. Garnacho-Montero J, Amaya-Villar R: Multiresistant Acinetobacter
baumannii infections: Epidemiology and management. Curr Opin
Infect Dis 2010; 23(4): 332-339
26. Ko Hj, Jeon Mh, Choo Ej, Lee Ej, Kim Th, Jun JB, Gil HW: Early
acute kidney injury is a risk factor that predicts mortality in patients
treated with colistin. Nephron Clin Pract 2011; 117(3): c284-288
27. Rattanaumpawan P, Ungprasert P, Thamlikitkul V: Risk factors for
colistin-associated nephrotoxicity. J Infect 2011; 62(2): 187-190
201
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal Hür E et al : Colistin and Acute Renal Failure
Turk Neph Dial Transpl 2014; 23 (3): 196-201
28. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K,
Vishnepolsky M, Weintrob A, Wortmann G: Nephrotoxicity
associated with intravenous colistin (colistimethate sodium)
treatment at a tertiary care medical center. Clin Infect Dis 2009;
48(12): 1724-1728
29. Falagas ME, Kasiakou SK: Toxicity of polymyxins: A systematic
review of the evidence from old and recent studies. Crit Care
2006;10(1):R27
30. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC,
Eaton AE: Adverse effects of sodium colistimethate. Manifestations
and specific reaction rates during 317 courses of therapy. Ann Intern
Med 1970;72(6):857-868
31. Beirne GJ, Hansing CE, Octaviano GN, Burns RO: Acute renal
failure caused by hypersensitivity to polymyxin B sulfate. JAMA
1967; 202(1): 156-158
32. Kallel H, Hamida CB, Ksibi H, Bahloul M, Hergafi L, Chaari A,
Chelly H, Bouaziz M: Suspected acute interstitial nephritis induced
by colistin. J Nephrol 2005; 18(3): 323-326
33. Mendes CA, Burdmann EA: Polymyxins - review with emphasis on
nephrotoxicity. Rev Assoc Med Bras 2009; 55(6): 752-759
34. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith
LB: Incidence and predictors of nephrotoxicity associated with
intravenous colistin in overweight and obese patients. Antimicrob
Agents Chemother 2012;56(5):2392-2396
35. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia
S, Miragliotta G, Bruno F, Brienza N: High-dose, extended-interval
colistin administration in critically ill patients: Is this the right
dosing strategy? A preliminary study. Clin Infect Dis 2012; 54(12):
1720-1726
Thank you for copying data from http://www.arastirmax.com
